Ginkgo Bioworks Holdings, Inc. (DNA): Price and Financial Metrics

Ginkgo Bioworks Holdings, Inc. (DNA): $3.21

0.25 (+8.45%)

POWR Rating

Component Grades













Add DNA to Watchlist
Sign Up

Industry: Biotech



in industry

DNA Stock Price Chart Interactive Chart >

Price chart for DNA

DNA Price/Volume Stats

Current price $3.21 52-week high $15.86
Prev. close $2.96 52-week low $2.09
Day low $2.96 Volume 20,886,400
Day high $3.22 Avg. volume 18,197,439
50-day MA $3.26 Dividend yield N/A
200-day MA $7.75 Market Cap 5.65B

Ginkgo Bioworks Holdings, Inc. (DNA) Company Bio

Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.

DNA Latest News Stream

Event/Time News Detail
Loading, please wait...

DNA Latest Social Stream

Loading social stream, please wait...

View Full DNA Social Stream

Latest DNA News From Around the Web

Below are the latest news stories about Ginkgo Bioworks Holdings Inc that investors may wish to consider to help them evaluate DNA as an investment opportunity.

Thursday’s Top Analysts Upgrades and Downgrades: Caesars Entertainment, Chevron, Exact Sciences, Exxon Mobil, Gap, Ginkgo Bioworks, Home Depot, New York Mortgage Trust, Novavax, NOV, SoFi Technologies and More

Thursday''s top analyst upgrades and downgrades included Caesars Entertainment, Chevron, Exact Sciences, Exxon Mobil, Gap, Ginkgo Bioworks, Home Depot, New York Mortgage Trust, Novavax, NOV and SoFi Technologies.

24/7 Wall street | February 24, 2022

Ginkgo Bioworks Announces Participation in Upcoming Conferences

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in the following upcoming conferences:

Yahoo | February 24, 2022

Ginkgo Bioworks, down 9% today, hits new post-IPO low

Ginkgo Bioworks (DNA) hit a post-IPO low of $4.24 today. The company began trading in September through a SPAC merger.

Seeking Alpha | February 22, 2022

Cronos Group Reports 2021 Third Quarter Results

Completed Audit Committee evaluation and restated Q2 2021 unaudited interim financial statements Announces strategic realignment to support future growth strategies Consolidated net revenue increased 80% in the third quarter of 2021 compared to the third quarter of 2020 Launched Cronos Group's first cultured cannabinoid gummy and vape products under Spinach FEELZ™ brand Spinach® held a double-digit market share in the gummies category in Canada in the third quarter of 2021 TORONTO, Feb. 18, 2022

Yahoo | February 18, 2022

7 Stocks to Buy After Sentiment Slipped to Lows

With sentiment souring over inflation and other concerns, contrarians may have an opportunity to bank on certain stocks to buy like these.

Josh Enomoto on InvestorPlace | February 17, 2022

Read More 'DNA' Stories Here

DNA Price Returns

1-mo 10.69%
3-mo -28.67%
6-mo -72.96%
1-year -67.48%
3-year N/A
5-year N/A
YTD -61.37%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4343 seconds.